Literature DB >> 17852797

Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis.

O E Johansen1.   

Abstract

Chronic hyperglycaemia (e.g. type 2 diabetes mellitus (T2DM) and prediabetes) in humans is associated with an increased risk of cardiovascular (CV) complications, and, vice versa, the presence of CV complications (e.g. myocardial infarction, stroke or intermittent claudication) among patients heightens the risk of T2DM or prediabetes. In both cases (i.e. chronic hyperglycaemia and CV complications), significant diagnostic and treatment challenges resulting from a broad range of factors may serve as barriers to reducing the deleterious societal impact of T2DM and prediabetes. These challenges often include clinicians: failing to intervene early and aggressively enough among patients with T2DM to achieve CV risk factor control; failing to efficaciously identify T2DM patients with already established CV complications; and failing proactively to assess individuals at high risk for T2DM. This review discusses the apparent symbiosis between CV disease and T2DM, with a focus on identifying patients with established T2DM or at risk for T2DM; traditional and novel risk factors and markers for CV disease in T2DM; challenges related to diagnosing CV disease in T2DM; and organization of T2DM care in order to prevent CV complications. These are issues that require attention because identifying patients at high risk for T2DM can halt or reduce their further glycaemic deterioration if addressed properly, and because novel markers and non-invasive tests could be applied in patients with T2DM as a means of detecting and possibly treating unrecognized CV disease in time. Furthermore, several approaches for T2DM care can be effective in controlling the CV risk factors contributing to CV complications.

Entities:  

Mesh:

Year:  2007        PMID: 17852797     DOI: 10.1080/00365510701408558

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  6 in total

1.  Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach.

Authors:  Odd Erik Johansen
Journal:  World J Diabetes       Date:  2015-08-10

2.  Metabolic Syndrome and its Profound Effect on Prevalence of Ischemic Stroke.

Authors:  Brandon P Lucke-Wold; Kenneth DiPasquale; Aric F Logsdon; Linda Nguyen; A Noelle Lucke-Wold; Ryan C Turner; Jason D Huber; Charles L Rosen
Journal:  Am Med Stud Res J       Date:  2014

Review 3.  SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Authors:  Silvio E Inzucchi; Bernard Zinman; Christoph Wanner; Roberto Ferrari; David Fitchett; Stefan Hantel; Rosa-Maria Espadero; Hans-Jürgen Woerle; Uli C Broedl; Odd Erik Johansen
Journal:  Diab Vasc Dis Res       Date:  2015-01-14       Impact factor: 3.291

4.  Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.

Authors:  Michael J Davies; Katherine Merton; Ujjwala Vijapurkar; Jacqueline Yee; Rong Qiu
Journal:  Cardiovasc Diabetol       Date:  2017-03-21       Impact factor: 9.951

Review 5.  The Impact of Selenium Deficiency on Cardiovascular Function.

Authors:  Briana K Shimada; Naghum Alfulaij; Lucia A Seale
Journal:  Int J Mol Sci       Date:  2021-10-02       Impact factor: 5.923

6.  Greater macrovascular and microvascular morbidity from type 2 diabetes in northern compared with southern China: A cross-sectional study.

Authors:  Li Wang; Ying Xing; Xinwen Yu; Jie Ming; Xiangyang Liu; Xiaomiao Li; Jianfang Fu; Jie Zhou; Bin Gao; Dayi Hu; Changyu Pan; Linong Ji; Qiuhe Ji
Journal:  J Diabetes Investig       Date:  2020-05-04       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.